Advanced Bionics and a major global pharmaceutical company join Spiral's Series B financing as new strategic investors, with Gund Investment leading the round and continued participation from Ferring Ventures, Uni-Bio Science Group and other existing investors.

Advanced Bionics 和一家全球主要制药公司作为新的战略投资者加入了Spiral的B轮融资，Gund Investment领投，Ferring Ventures、Uni-Bio Science Group和其他现有投资者继续参与。

R&D collaboration combines Advanced Bionics' global leadership in cochlear implant technology with Spiral's expertise in developing novel therapeutics for inner ear disorders.

研发合作将Advanced Bionics在全球人工耳蜗技术领域的领导地位与Spiral在开发内耳疾病新型疗法方面的专业知识相结合。

Proceeds from the transactions will support the development of Spiral's pipeline programs including SPT-2101 and expansion of Spiral's proprietary MICS™ platform.

交易所得将用于支持Spiral的管道项目（包括SPT-2101）的开发，以及扩展Spiral专有的MICS™平台。

SOUTH SAN FRANCISCO, Calif.

加利福尼亚州南旧金山

,

，

April 14, 2026

2026年4月14日

/PRNewswire/ -- Spiral Therapeutics, Inc. ('Spiral Therapeutics' or 'Spiral'), a clinical-stage company developing novel therapies for inner ear disorders, today announced the closing of its $27 million Series B financing. The financing, led by Gund Investment, includes new strategic participation from Advanced Bionics and a major global pharmaceutical company, alongside continued participation from Ferring Ventures, Uni-Bio Science Group and other existing investors..

/PRNewswire/ -- Spiral Therapeutics, Inc.（“Spiral Therapeutics”或“Spiral”），一家致力于开发内耳疾病新型疗法的临床阶段公司，今天宣布完成了2700万美元的B轮融资。本轮融资由Gund Investment领投，新加入的战略投资者包括Advanced Bionics和一家全球领先的制药公司，同时Ferring Ventures、Uni-Bio Science Group以及其他现有投资者继续参与。

Concurrent with the financing, Spiral entered into a strategic R&D collaboration with Advanced Bionics to explore sustained local drug delivery at the time of cochlear implantation to meaningfully improve outcomes for cochlear implant recipients.

与此同时，Spiral与Advanced Bionics建立了战略研发合作关系，在人工耳蜗植入时探索持续局部药物递送，以显著改善人工耳蜗接受者的治疗效果。

'This financing is a major milestone for Spiral. It brings Advanced Bionics on as a strategic partner, welcomes Gund Investment as our Series B lead, and reinforces the continued support of our existing investors,' said Hugo Peris, Founder and CEO of Spiral Therapeutics. 'Inner ear disorders are finally gaining the strategic attention long warranted by their prevalence and impact.

“这笔融资是Spiral公司的一个重要里程碑。它使Advanced Bionics成为我们的战略合作伙伴，迎来了Gund Investment作为我们B轮融资的领投方，并加强了现有投资者的持续支持，”Spiral Therapeutics创始人兼首席执行官Hugo Peris表示。“内耳疾病终于因其普遍性和影响而获得了应有的战略关注。”

Spiral stands out as one of a select few companies with a truly differentiated platform capable of enabling a robust pipeline of inner ear therapeutics.'.

螺旋公司脱颖而出，成为少数几家拥有真正差异化平台的公司之一，该平台能够助力丰富的耳内治疗药物管线。

Spiral is advancing a pipeline of programs targeting diseases of the inner ear. Its lead program, SPT-2101, delivered a statistically significant reduction of overall vertigo in patients with Ménière's disease, and the company is preparing for a registrational clinical trial. Spiral's MICS™ (

螺旋公司正在推进一系列针对内耳疾病的项目。其主导项目SPT-2101在梅尼埃病患者中显著减少了总体眩晕，并且公司正准备进行注册临床试验。螺旋公司的MICS™（

M

M

inimally-

最少的-

I

我

nvasive

侵入性的

C

C

ochlear

耳蜗的

S

S

ystem) drug delivery platform underpins a broader portfolio of hearing loss programs, including neurotrophic approaches designed to target fundamental disease pathobiology.

系统）药物递送平台支撑着更广泛的听力损失项目组合，包括旨在针对基本疾病病理生物学的神经营养方法。

Despite representing a significant area of unmet medical need, the inner ear remains one of the least innovated therapeutic spaces in medicine. Spiral is well positioned to address this disparity through precision delivery technologies capable of unlocking new treatment paradigms across multiple otologic indications..

尽管内耳代表着一个巨大的未满足医疗需求的领域，但它仍然是医学界最少创新的治疗领域之一。Spiral 有望通过精准递送技术解决这一差距，这些技术能够为多种耳科适应症开启新的治疗模式。

About Spiral Therapeutics

关于Spiral Therapeutics

Spiral Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for inner ear disorders, including hearing loss and balance disorders. Spiral's MICS™ (

Spiral Therapeutics是一家临床阶段的生物技术公司，专注于开发针对内耳疾病的新型疗法，包括听力损失和平衡障碍。Spiral的MICS™（

M

M

inimally-

最小化-

I

我

nvasive

侵入性的

C

C

ochlear

耳蜗的

S

S

ystem) drug delivery platform is designed to enable minimally invasive, precise and durable exposure of therapeutics to the cochlea. The company is advancing a pipeline of programs intended to address significant unmet needs across inner ear diseases.

系统）药物递送平台旨在实现微创、精准且持久的耳蜗治疗暴露。该公司正在推进一系列项目，旨在满足内耳疾病领域大量未被满足的需求。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements, including statements regarding Spiral's development plans, including initiation of its registrational clinical trial, Spiral's strategic collaboration with Advanced Bionics, and the potential development and commercialization of SPT-2101 and other pipeline programs, including Spiral's position to address the disparity of innovations in inner ear medicine.

本新闻稿包含前瞻性声明，包括关于Spiral的开发计划的声明，包括启动其注册临床试验、Spiral与Advanced Bionics的战略合作，以及SPT-2101和其他管线项目潜在的开发和商业化，包括Spiral在解决内耳医学创新差距方面的地位。

These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Spiral undertakes no obligation to update these statements except as required by law..

这些声明基于当前的预期和假设，并受到可能致使实际结果产生重大差异的风险和不确定性的约束。Spiral 除法律要求外，没有义务更新这些声明。

Contact

联系

Hugo Peris, CEO

雨果·佩里斯，首席执行官

(650) 453-0893

(650) 453-0893

[email protected]

电子邮件地址

SOURCE Spiral Therapeutics, Inc.

来源：Spiral Therapeutics, Inc.

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示